PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV , an.
PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October.
INNOVATIVE ACCESS DEAL SECURED IN THE UK FOR LYNPARZA (OLAPARIB) TO TREAT BRCA-MUTATED CANCERS Olaparib is the first and only treatment available within NHS England for patients with germline BRCA mutations in early breast cancer (stage I-IIIA) and patients with metastatic castration-resistant prostate cancer (.
STRICTLY EMBARGOED UNTIL Tuesday 6 September 2022 00:01 BST LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER First and only approved medicine in Great Britain which targets germline BRCA mutations in pati.
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer - read this article along with other careers information, tips and advice on BioSpace